Earnings Feed
Start Free
Home/Filings/4/0001415889-17-001636
4//SEC Filing

Baity Glenn 4

Accession 0001415889-17-001636

CIK 0001070494other
View on SEC.govCompany Profile

Filed

Oct 5, 8:00 PM ET

Accepted

Oct 6, 6:20 PM ET

Size

23.8 KB

Accession

0001415889-17-001636

Insider Transaction Report

Form 4
Period: 2017-10-04
ACADIA PHARMACEUTICALS INCACAD
Baity Glenn
VP, GC & Sec.
Transactions
  • Exercise/Conversion

    Common Stock

    2017-10-04$2.18/sh+4,500$9,810→ 78,656 total
  • Exercise/Conversion

    Common Stock

    2017-10-05$1.62/sh+7,500$12,150→ 99,656 total
  • Sale

    Common Stock

    2017-10-05$40.91/sh−37,500$1,534,043→ 69,656 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-10-04−6,500→ 7,500 total
    Exercise: $1.62Exp: 2021-03-24→ Common Stock (6,500 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-10-04−4,500→ 125,500 total
    Exercise: $2.18Exp: 2022-03-22→ Common Stock (4,500 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-10-05−1,000→ 124,500 total
    Exercise: $2.18Exp: 2022-03-22→ Common Stock (1,000 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-10-05−7,500→ 0 total
    Exercise: $1.62Exp: 2021-03-24→ Common Stock (7,500 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2017-10-05−20,000→ 0 total
    Exercise: $2.00Exp: 2018-10-19→ Common Stock (20,000 underlying)
  • Exercise/Conversion

    Common Stock

    2017-10-04$1.62/sh+6,500$10,530→ 74,156 total
  • Exercise/Conversion

    Common Stock

    2017-10-05$2.18/sh+1,000$2,180→ 79,656 total
  • Exercise/Conversion

    Common Stock

    2017-10-05$2.00/sh+20,000$40,000→ 107,156 total
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.605 to $41.065 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
  • [F3]25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
  • [F4]25% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
  • [F5]50% of the shares subject to the Stock Option vested and became exercisable on October 20, 2010. The remaining shares vested and became exercisable thereafter in 24 equal monthly installments.

Documents

1 file

Issuer

ACADIA PHARMACEUTICALS INC

CIK 0001070494

→
Entity typeother

Related Parties

1
  • filerCIK 0001487100

Filing Metadata

Form type
4
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 6:20 PM ET
Size
23.8 KB
View on SEC.gov